GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » Net Cash per Share

Betta Pharmaceuticals Co (SZSE:300558) Net Cash per Share : ¥-7.77 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Betta Pharmaceuticals Co's Net Cash per Share for the quarter that ended in Mar. 2024 was ¥-7.77.

The historical rank and industry rank for Betta Pharmaceuticals Co's Net Cash per Share or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Cash Ratio of Betta Pharmaceuticals Co was 407.00. The lowest was 150.77. And the median was 264.06.

SZSE:300558's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.045
* Ranked among companies with meaningful Price-to-Net-Cash only.

Betta Pharmaceuticals Co Net Cash per Share Historical Data

The historical data trend for Betta Pharmaceuticals Co's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co Net Cash per Share Chart

Betta Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.87 0.60 -1.73 -5.58 -7.51

Betta Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.99 -6.91 -6.90 -7.51 -7.77

Competitive Comparison of Betta Pharmaceuticals Co's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Betta Pharmaceuticals Co's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Betta Pharmaceuticals Co's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Betta Pharmaceuticals Co's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Betta Pharmaceuticals Co's Price-to-Net-Cash falls into.



Betta Pharmaceuticals Co Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Betta Pharmaceuticals Co's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(752.536-3795.435-100.397)/418.486
=-7.51

Betta Pharmaceuticals Co's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

Net Cash per Share (Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(554.561-3713.62-90.665)/418.486
=-7.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Betta Pharmaceuticals Co  (SZSE:300558) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Betta Pharmaceuticals Co Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Betta Pharmaceuticals Co (SZSE:300558) Business Description

Traded in Other Exchanges
N/A
Address
No.355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Zhejiang Province, Hangzhou, CHN
Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.
Executives
Wang Jia Bing Directors, executives
Ding Lie Ming Directors, executives
Cai Wan Yu Executives

Betta Pharmaceuticals Co (SZSE:300558) Headlines

No Headlines